Home pageSGIOY • OTCMKTS
add
Shionogi & Co.
Chiusura precedente
6,93 $
Intervallo giornaliero
6,94 $ - 7,03 $
Intervallo annuale
6,22 $ - 9,11 $
Cap di mercato
1,87 Bln JPY
Volume medio
233.490,00
Notizie
Simply Wall Street
1 giorno fa
There's Reason For Concern Over Shionogi & Co., Ltd.'s (TSE:4507) Price
0,094%
Dati finanziari
Conto economico
Entrate
Utile netto
| (JPY) | set 2024info | Variazione Y/Y |
|---|---|---|
Entrate | 116,38 Mld | -4,00% |
Spese di gestione | 52,93 Mld | -3,66% |
Utile netto | 52,50 Mld | 9,30% |
Margine di profitto netto | 45,11 | 13,86% |
Utili per azione | — | — |
EBITDA | 53,13 Mld | -5,14% |
Aliquota fiscale effettiva | 8,28% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (JPY) | set 2024info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 303,40 Mld | 20,22% |
Totale attivo | 1,46 Bln | 3,34% |
Totale passivo | 145,93 Mld | -18,09% |
Patrimonio netto totale | 1,31 Bln | — |
Azioni in circolazione | 850,69 Mln | — |
Prezzo/valore contabile | 0,00 | — |
Redditività dell'attivo | 8,22% | — |
Rendimento sul capitale | 9,10% | — |
Flusso di cassa
Flusso di cassa netto
| (JPY) | set 2024info | Variazione Y/Y |
|---|---|---|
Utile netto | 52,50 Mld | 9,30% |
Liquidità di esercizio | 45,30 Mld | 220,14% |
Contanti da investimenti | -17,63 Mld | 47,30% |
Contanti da finanziamenti | -1,11 Mld | 94,50% |
Flusso di cassa netto | 21,45 Mld | 158,43% |
Flusso di cassa libero | 8,02 Mld | 135,46% |
Informazioni
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Fondazione
1878
Sito web
Dipendenti
4.959
